Search results for: Jorge Mestre-Ferrandiz
Filter search results
Recently Published: Payer Perspectives on Future Acceptability of Comparative Effectiveness and Relative Effectiveness Research
18 August 2015
…Journal of Comparative Effectiveness Research (Epub ahead of print). Download the full paper here. For more information on OHE’s research in this area, please contact Adrian Towse or Jorge Mestre-Ferrandiz….
Multi-indication Pricing: Pros, Cons and Applicability to the UK
28 October 2015
…welcome this direction of travel, with MIP being one of the approaches that could be adopted. Access the full briefing here. For more information contact Dr Jorge Mestre-Ferrandiz at OHE….
Newly Published Analysis: Dementia: the R&D Landscape
16 November 2015
…and Dr Jorge Mestre-Ferrandiz for Imperial College and the UK Department of Health. The report contains three main sections: A brief overview of the current thinking on the reasons for…
Biosimilars: How Much Entry and Price Competition Will Result?
1 December 2010
…impact. Chapter authors include Profs Bengt Jönsson (Stockholm School of Economics), Prof Henry Grabowski (Duke University), Prof Adrian Towse and Dr. Jorge Mestre-Ferrandiz (OHE), Prof Richard G. Frank (Harvard Medical…
OHE at the 2019 Spanish Health Economics Association (AES) Conference
5 June 2019
…Greece. Time until results are available was the least important attribute in most countries. This presentation will be given by OHE Visiting Fellow, Jorge Mestre-Ferrandiz. Poster session IV, P-51: Blood…
OHE Posters at HTAi: Tokyo 2016
24 May 2016
…and Karla Hernandez-Villafuerte at the meeting can be found in a previous blog post. Multi-Indication Pricing: Pros, Cons and Applicability by Jorge Mestre-Ferrandiz Multi-indication pricing (MIP) involves setting a different price…
An Insurance Framework for Funding New Antibiotics
22 September 2017
…on a Policy of Risk Mitigation” has been published online in Health Policy OHE Director Adrian Towse and OHE Visiting Fellow Jorge Mestre-Ferrandiz are co-authors along with Chris Hoyle, Jonathan…
OHE at AES 2016: Early Access Schemes, Equity Adjusted QALYs, Multi-indication Pricing and Formulary Development
2 August 2016
…their activity. Multi-Indication Pricing: Pros, Cons and Applicability to the UK by Jorge Mestre-Ferrandiz Multi-indication pricing (MIP) involves setting a different price for each indication approved for a medicine. The…
The Value of Knowing and Knowing the Value: Improving the Health Technology Assessment of Complementary Diagnostics
5 July 2016
…I: Complementary Diagnostics: A Literature Review on the Value of Knowing Appendix Two: Phase II: Landscape Review of Complementary Diagnostics in Europe For more information, please contact Dr Jorge Mestre-Ferrandiz…